Understanding JDRF’s Mission to Revolutionize Glucose Monitoring for Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune condition that destroys the insulin-producing beta cells in the pancreas. Without insulin, the body cannot regulate blood glucose (sugar) levels, leading to acute and long-term complications. For the roughly 1.45 million Americans living with T1D, managing blood glucose is a 24/7 responsibility. Traditional finger-prick testing, while effective, is painful, inconvenient, and provides only a snapshot of glucose levels at a single point in time. The Juvenile Diabetes Research Foundation (JDRF) has long recognized that improving glucose monitoring devices is one of the most impactful ways to enhance daily life for T1D patients. Through funding cutting-edge research, forging industry partnerships, and advocating for regulatory changes, JDRF is driving the development of more accurate, less invasive, and smarter monitoring systems. This article explores the organization’s ongoing efforts, the innovations it supports, and the challenges that remain on the road to a fully automated, closed-loop future.

Why Glucose Monitoring Matters More Than Ever

Blood glucose monitoring is the foundation of T1D management. Patients use the data to make decisions about insulin dosing, food intake, and physical activity. Poorly controlled glucose levels can lead to hypoglycemia (dangerously low blood sugar), hyperglycemia (high blood sugar), and over time, complications such as retinopathy, neuropathy, kidney disease, and cardiovascular problems. The advent of continuous glucose monitors (CGMs) has transformed care by providing real-time trends and alerts, but even state-of-the-art CGMs have limitations—accuracy can drift, sensors require regular replacement, and insertion still involves a needle. JDRF’s mission is to push beyond these constraints, aiming for devices that are not only more precise but also seamless, affordable, and eventually non-invasive.

A Historical Perspective: JDRF’s Role in Shaping Glucose Monitoring Technology

JDRF was founded in 1970 by parents of children with T1D who were frustrated by the slow pace of research. From the beginning, the foundation focused on accelerating the development of a cure, but it also recognized the urgent need to improve day-to-day management tools. In the late 1990s and early 2000s, JDRF invested heavily in CGM technology, providing seed funding for companies like Dexcom and Medtronic. These early investments helped bring the first generation of CGMs to market. JDRF also funded clinical studies that demonstrated the benefits of CGM use, paving the way for insurance coverage and FDA approval. Today, JDRF continues to fund both early-stage research and late-stage translation, working with academic labs, startups, and established medtech firms.

Core Areas of JDRF’s Glucose Monitoring Focus

Continuous Glucose Monitors (CGMs): The Current Gold Standard

CGMs are wearable sensors that measure glucose levels in interstitial fluid every few minutes, transmitting data to a receiver or smartphone. JDRF supports efforts to make CGMs more accurate, longer-lasting, and less burdensome. Current research includes:

  • Improved sensor algorithms: Developing software that can better filter noise, detect calibration drift, and predict glucose trends. JDRF-funded research at the University of California, Santa Barbara, for example, has led to advanced predictive algorithms now used in commercial CGMs.
  • Extended wear duration: Most sensors need replacement every 7–14 days. JDRF is backing projects to create sensors that last for 30 days or more, reducing the frequency of insertion and medical waste.
  • Reduced calibration needs: Early CGMs required twice-daily finger sticks for calibration. JDRF helped fund the development of “factory-calibrated” sensors that need no user calibration, such as the Dexcom G6 and G7.

Non-Invasive and Minimally Invasive Technologies

A key goal for JDRF is to eliminate the needle entirely. Several approaches are under investigation:

  • Optical sensors: Using near-infrared, Raman spectroscopy, or photoacoustic techniques to measure glucose through the skin. JDRF has funded work at MIT and other institutions exploring these methods. While progress has been slow due to interference from water, lipids, and melanin, recent advances in machine learning are improving signal processing.
  • Microneedle arrays: Arrays of tiny needles that penetrate only the outer layer of skin, causing no pain. They can measure glucose in interstitial fluid or even deliver insulin. JDRF is supporting companies like Bioling and Incube Labs in this space.
  • Fluorescent sensors: Implantable or injectable hydrogels that change fluorescence in response to glucose, read by an external monitor. JDRF has funded research at the University of Connecticut and elsewhere.
  • Wearable patches and tattoos: Flexible patches that stick to the skin and use sweat, tears, or other biofluids to measure glucose. JDRF is co-funding the JDRF T1D Fund portfolio company Leman Micro Devices on a non-invasive patch.

The Artificial Pancreas: Integrating Monitoring with Insulin Delivery

JDRF has been a driving force behind the development of hybrid closed-loop systems, commonly called artificial pancreases. These systems combine a CGM, an insulin pump, and a control algorithm to automatically adjust insulin delivery based on glucose readings. JDRF funded the first outpatient clinical trials of closed-loop systems and continues to support the next generation:

  • Dual-hormone systems: Adding a glucagon pump to prevent hypoglycemia. JDRF-supported research at the University of British Columbia has shown promising results.
  • Fully closed loops: Systems that require no meal announcements or manual corrections. JDRF is funding algorithm development at institutions like the University of Cambridge.
  • Do-it-yourself (DIY) looping: JDRF has taken a neutral-to-supportive stance on community-built systems like OpenAPS and Loop, advocating for regulatory pathways that allow innovation while ensuring safety.

Advanced Sensor Accuracy and Reliability

Accuracy remains a top priority. Even the best CGMs have a mean absolute relative difference (MARD) of around 8–10%. JDRF funds projects to push MARD below 5%, especially in hypoglycemic ranges. Research includes:

  • Redox mediators: New sensor chemistries that are less prone to interference from drugs like acetaminophen.
  • Biofouling-resistant coatings: Materials that prevent the body’s immune response from degrading sensor performance.
  • Redundant sensors: Using multiple electrodes to cross-check readings, increasing reliability.

Overcoming Barriers: JDRF’s Advocacy and Policy Work

Technology alone is not enough. JDRF actively works to remove barriers that prevent patients from accessing the best glucose monitoring devices:

  • Insurance and reimbursement: JDRF lobbies Medicare, Medicaid, and private insurers to cover CGMs and artificial pancreas systems for all people with T1D, not just those meeting strict criteria. In 2017, JDRF’s advocacy helped secure Medicare coverage for CGMs.
  • Regulatory innovation: JDRF works with the FDA to create flexible review pathways for novel devices, such as the Earliest Feasibility Study program, which allows small, early-stage clinical trials.
  • Standardization: JDRF participates in international efforts to standardize CGM accuracy metrics and interoperability, ensuring that devices from different manufacturers can work together seamlessly.
  • Affordability: The JDRF T1D Fund invests in companies developing lower-cost sensors and manufacturing processes to reduce the financial burden on patients.

JDRF’s Strategic Partnerships and Funding Initiatives

JDRF does not work in isolation. It collaborates with academic institutions, government agencies, and industry leaders to accelerate progress. Notable initiatives include:

  • JDRF-Sanofi Global Research Program: A $20 million partnership to fund projects in closed-loop control, sensor integration, and novel biomarkers.
  • JDRF-Merck KGaA collaboration: Focused on developing non-invasive glucose monitoring technologies using optical and metabolic sensors.
  • JDRF-T1D Exchange: A partnership that collects real-world data from thousands of patients to identify what works and what needs improvement in current monitoring devices.
  • Innovation platforms: JDRF runs an annual “Innovation Challenge” that awards grants to startups with breakthrough ideas in glucose sensing. Past winners include Directus (not the CMS, but a different entity) and Semma Therapeutics (now part of Vertex) for cell-based sensors.

Patient-Centered Design: How JDRF Incorporates User Feedback

To ensure devices meet real-world needs, JDRF involves patients, caregivers, and clinicians at every stage. The foundation conducts focus groups, surveys, and usability studies. Key patient priorities that JDRF addresses include:

  • Discreetness: Smaller, more flexible sensors that can be worn under clothing without noticeable bulges. JDRF funded the development of a prototype “sticker-sized” CGM.
  • Ease of use: Simplified insertion devices, smartphone apps with intuitive interfaces, and Bluetooth connectivity that eliminates the need for a separate receiver.
  • Reduced alarm fatigue: Smarter alerts that prioritize actionable events and avoid unnecessary notifications. JDRF-supported research on predictive algorithms has already reduced false alarms by 40% in some systems.
  • Comfort: Hypoallergenic adhesives, flexible sensor filaments, and sensors that can be placed on multiple body sites (arm, abdomen, upper leg).

Future Directions: JDRF’s Vision for Glucose Monitoring in 2030

Looking ahead, JDRF envisions a world where glucose monitoring is virtually invisible and fully integrated into a patient’s life. The foundation prioritizes several long-term research goals:

Biocompatible Implantable Sensors

Small, long-lasting implants placed under the skin that communicate wirelessly with a smartphone. JDRF is funding research into biodegradable materials and power harvesting (e.g., using the body’s own glucose as a fuel source) to create sensors that last for years.

Multimodal Sensing

Combining glucose data with other vital signs—heart rate, skin temperature, activity level—to provide a more complete picture of a patient’s metabolic state. JDRF-supported projects at the University of Michigan are developing wrist-worn bands that measure glucose via Raman spectroscopy and EKG simultaneously.

Closed-Loop Pancreas with Predictive Control

The ultimate goal: a system that not only reacts to glucose levels but also anticipates them using machine learning. JDRF funds work on “model predictive control” algorithms that factor in meal timing, exercise routines, and even stress levels to achieve near-normal glucose levels without user input.

Global Accessibility

JDRF is expanding its focus to low- and middle-income countries where access to modern glucose monitoring is limited. The foundation supports research into low-cost, disposable sensors that can be manufactured locally, as well as smartphone-based diagnostic apps that work without expensive hardware.

How the Public Can Support JDRF’s Mission

JDRF’s progress depends on a broad community of supporters. Individuals can contribute in several meaningful ways:

  • Participate in research: JDRF runs outreach programs that match T1D patients with clinical trials for new monitoring devices. Sign up at the JDRF website to receive trial notifications.
  • Fundraise: Host a local Walk, Ride, or Run to Cure Diabetes event. JDRF’s flagship fundraising program has raised hundreds of millions for research.
  • Advocate: Contact your elected officials to support increased federal funding for diabetes research and to protect insurance coverage for CGMs. JDRF provides advocacy toolkits and training.
  • Spread awareness: Share personal stories and information about the importance of glucose monitoring on social media. JDRF’s #WeAreJDRF campaign amplifies patient voices.
  • Donate: Direct financial contributions allow JDRF to fund the highest-risk, highest-reward research that industry may ignore. Even small donations add up.

Conclusion: A Future Within Reach

The path to better glucose monitoring devices is neither short nor simple, but JDRF’s sustained commitment is yielding tangible results. From the first generation of CGMs to today’s advanced closed-loop systems, the foundation has been a catalyst for change. As research continues to overcome challenges in accuracy, affordability, and user experience, the prospect of a truly hands-off, non-invasive monitoring system—and eventually a cure—grows brighter. By supporting JDRF’s work, every patient, family member, and advocate plays a critical role in shaping the future of T1D care. The goal is not just better devices but a better quality of life for millions of people worldwide.